A detailed history of Prestige Wealth Management Group LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Prestige Wealth Management Group LLC holds 472 shares of ALNY stock, worth $118,486. This represents 0.02% of its overall portfolio holdings.

Number of Shares
472
Previous 278 69.78%
Holding current value
$118,486
Previous $53,000 32.08%
% of portfolio
0.02%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 26, 2024

BUY
$146.51 - $198.2 $28,422 - $38,450
194 Added 69.78%
472 $70,000
Q4 2023

Apr 26, 2024

SELL
$151.41 - $196.57 $5,450 - $7,076
-36 Reduced 11.46%
278 $53,000
Q4 2023

Feb 08, 2024

SELL
$151.41 - $196.57 $5,450 - $7,076
-36 Reduced 11.46%
278 $53,000
Q3 2023

Apr 26, 2024

BUY
$170.77 - $211.65 $51,914 - $64,341
304 Added 3040.0%
314 $55,000
Q3 2023

Nov 13, 2023

BUY
$170.77 - $211.65 $51,914 - $64,341
304 Added 3040.0%
314 $55,000
Q1 2023

Apr 26, 2024

SELL
$182.66 - $235.53 $84,388 - $108,814
-462 Reduced 97.88%
10 $2,000
Q1 2023

May 16, 2023

BUY
$182.66 - $235.53 $547 - $706
3 Added 42.86%
10 $2,000
Q4 2022

Feb 07, 2023

SELL
$185.53 - $241.31 $5,565 - $7,239
-30 Reduced 81.08%
7 $1,000
Q3 2022

Nov 01, 2022

SELL
$138.54 - $232.0 $205,039 - $343,360
-1,480 Reduced 97.56%
37 $7,000
Q2 2022

Aug 10, 2022

BUY
$120.42 - $169.29 $35,283 - $49,601
293 Added 23.94%
1,517 $221,000
Q1 2022

May 05, 2022

BUY
$127.18 - $173.91 $76,308 - $104,346
600 Added 96.15%
1,224 $200,000
Q4 2021

Feb 15, 2022

BUY
$159.56 - $209.29 $92,544 - $121,388
580 Added 1318.18%
624 $105,000
Q3 2021

Nov 12, 2021

BUY
$169.75 - $207.73 $2,376 - $2,908
14 Added 46.67%
44 $9,000
Q1 2020

May 15, 2020

BUY
$93.12 - $133.99 $2,793 - $4,019
30 New
30 $3,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30.9B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Prestige Wealth Management Group LLC Portfolio

Follow Prestige Wealth Management Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prestige Wealth Management Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prestige Wealth Management Group LLC with notifications on news.